GO:0035335 peptidyl-tyrosine dephosphorylation

Peptidyl-tyrosine dephosphorylation (GO:0035335) is the enzymatic removal of phosphate groups from tyrosine residues on proteins, a fundamental post-translational modification that counterbalances tyrosine kinase signaling. This process is essential for controlling cell growth, differentiation, metabolism, and immune responses, and its dysregulation is linked to cancer, diabetes, and developmental disorders. Protein tyrosine phosphatases (PTPs) catalyze this reaction with high substrate specificity, and their activity is tightly regulated in space and time. Researchers study peptidyl-tyrosine dephosphorylation to understand how signaling pathways are switched off, how PTP mutations cause disease, and how pharmacological modulation of PTPs can be exploited therapeutically. Recent work has shown that PTPN1 (PTP1B) is regulated by microRNAs such as miR-124-3p during testicular development and spermatogenesis, highlighting the importance of this process in reproductive biology. In addition, computational analyses of salt-sensitive hypertension have identified ceRNA networks involving PTPN1, linking peptidyl-tyrosine dephosphorylation to cardiovascular pathology. Given its broad impact, peptidyl-tyrosine dephosphorylation is a high-value target for functional genomics. CRISPR-based knockout, point-mutation, knock-in, and overexpression models allow researchers to test causality of specific PTP genes and their regulatory elements in physiologically relevant systems [1,2].

Peptidyl-tyrosine dephosphorylation (GO:0035335) is defined by the Gene Ontology as the removal of phosphoric residues from peptidyl-O-phospho-tyrosine to form peptidyl-tyrosine. In simpler terms, it is the process by which enzymes called protein tyrosine phosphatases (PTPs) strip a phosphate group off a tyrosine amino acid within a protein, thereby reversing the action of tyrosine kinases. This reaction is a key regulatory switch in signal transduction, and it is essential for normal cellular physiology.

Peptidyl-tyrosine dephosphorylation is critically important because it provides the off-switch for tyrosine phosphorylation, a modification that controls virtually every aspect of cell behavior. Without proper PTP activity, cells cannot terminate growth factor, insulin, or immune signaling, leading to uncontrolled proliferation, metabolic dysfunction, or autoimmunity. Moreover, PTPs are frequently mutated or dysregulated in human diseases, and they are attractive drug targets. Understanding this process at the molecular level is therefore essential for both basic biology and translational medicine [1,2].

The following genes and proteins are central to peptidyl-tyrosine dephosphorylation, as supported by the verified literature.

Peptidyl-tyrosine dephosphorylation is regulated at multiple levels. At the post-transcriptional level, microRNAs such as miR-124-3p directly target PTPN1 mRNA, reducing phosphatase levels and thereby modulating testicular development and spermatogenesis in mice. In salt-sensitive hypertension, a ceRNA network involving PTPN1 suggests that competing endogenous RNAs sequester microRNAs and indirectly influence phosphatase expression. Additionally, PTP activity can be regulated by reversible oxidation of the catalytic cysteine, phosphorylation, and protein-protein interactions. These regulatory mechanisms ensure that dephosphorylation is temporally and spatially controlled [1,2].

Dysregulation of peptidyl-tyrosine dephosphorylation can impair testicular development and spermatogenesis. miR-124-3p regulates Ptpn1 expression in mouse testis, and perturbation of this axis affects germ cell development. This suggests that PTPN1 and its regulators are candidate genes for male infertility research.

A ceRNA network analysis identified PTPN1 as a key node in salt-sensitive hypertension, linking peptidyl-tyrosine dephosphorylation to blood pressure regulation. The study constructed a network of mRNAs, microRNAs, and circRNAs, highlighting PTPN1 as a potential biomarker or therapeutic target.

Circular RNA profiling in radiation-treated HeLa cells revealed changes in circRNAs that may regulate radioresistance, a process in which tyrosine phosphatase signaling could play a role. Although direct evidence for PTP involvement is limited in this dataset, the study provides a resource for investigating dephosphorylation in cancer therapy response.

CRISPR-Cas9 knockout of PTP genes allows researchers to test loss-of-function phenotypes in cell lines and animal models. Point-mutation knock-in can be used to dissect catalytic residues or regulatory phosphorylation sites. These approaches are essential for establishing causality in peptidyl-tyrosine dephosphorylation research.

RNA sequencing followed by ceRNA network construction can identify microRNAs and circRNAs that regulate PTP expression, as demonstrated in salt-sensitive hypertension. This method reveals post-transcriptional layers controlling dephosphorylation.

Circular RNA expression profiling in radiation-treated HeLa cells identified circRNAs potentially involved in radioresistance, providing a resource for studying dephosphorylation in cancer therapy. Follow-up functional studies can test whether these circRNAs modulate PTP activity.

Mass spectrometry-based phosphoproteomics can quantify changes in tyrosine phosphorylation upon PTP perturbation, revealing direct and indirect substrates. This method is powerful for mapping the landscape of peptidyl-tyrosine dephosphorylation.

Researchers studying peptidyl-tyrosine dephosphorylation-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway, developmental process, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation of PTP genes and their regulators.

Peptidyl-tyrosine dephosphorylation (GO:0035335) is a fundamental biological process that reverses tyrosine phosphorylation and controls a wide range of cellular functions. Its dysregulation contributes to cancer, metabolic disorders, hypertension, and reproductive defects, making it a high-priority area for functional genomics [1,2,3]. CRISPR-based models and bioinformatics approaches are indispensable for dissecting the causal roles of PTPs and their regulators [1,2]. EDITGENE provides comprehensive CRISPR services, including knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics, to accelerate research on peptidyl-tyrosine dephosphorylation and its associated diseases.